Home EtrenaTrex®250

EtrenaTrex®250 10ml vial

Trenbolone Enanthate 250mg/ml, 10 mL Multidose Vial



Therapeutic Class:
Anabolic Agent


Each 1 ml of ETRENATREX250 contains

250 mg Trenbolone Enanthate

Ethlyl Oleate q.s.

For Intramuscular Administration

Indication & Dosage:

Certain pathophysiological or catabolic processes in animals.
As anabolic after debilitating illness

The dosage for cattle is 0.55 to 2.1 mg/ of animal body

weight intramuscularly. Treatment may be repeated every 2 to 3 weeks.

The condition should be assessed by a veterinarian to determine the

duration of treatment; however, most horses will respond with one or two treatments.


In the absence of data on the effect of trenbolone enanthate on immature colts and

fillies, stallions, pregnant mares or brood mares during the breeding season, this drug should not be used in these animals.

    Special Precautions          
For feedlot catlle only. This drug is not to be administered to horses that are to be slaughtered
for use in food. Keep out of reach of children.

    Adverse Drug Reactions   
Treatment with ETRENANTREX injectable (trenbolone enanthate injection) may
result in androgenic effects (masculinization, behavioural effects) being expressed
in some animals. If these effects occur, they may persist for up to 6 to 8 weeks.
No additional injections of boldenone undecylenate should be administered.

    Drug Interactions               

May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).

    Pregnancy Category
Category X: Studies in animals beings have demonstrated foetal abnormalities or there is evidence of foetal risk.


Store at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly-closed container. Store away from heat, moisture, and light.

Do not store in the bathroom. Keep out of the reach of children and away from pets.

Concentrex Laboratiories N. V., Moerstraat 58, 9031, Gent, Belgium

Reg. No. Licence: 253/55-C9/2010/BE
Manufactured under WHO cGMP guidelines
Date of Preparation : 19 july 2010